Aktuell
Octapharma submits marketing authorization application (MAA) to the EMA for the first truly human recombinant coagulation factor VIII from a human cell line
März 2013
Octapharma Group release 2012 Annual Report
Februar 2013
Two more new peer-reviewed publications on human cell line-derived recombinant human FVIII
September 2012
Peer-reviewed paper about our rhFVIII-Projekt
April 2012
Standortverlegung der Octapharma Biopharmaceuticals GmbH
Octapharma investiert im Technologiepark Heidelberg
Octapharma AG submitted the marketing authorization application (MAA) for the first truly human recombinant coagulation factor VIII (FVIII) from a human cell line for the treatment of haemophilia A to the European Medicines Agency (EMA) on May 29th, 2013.
www.octapharma.com/en/about-octapharma/news-events/news-single-view.html?tx_ttnews%5Btt_news%5D=332&cHash=76e7393e88a4145e11ec3d7c95fabd96
------------------------------------------------------------
An impressive return of octagam® 5% and 10% consolidated the financial performance and financial position of the Octapharma Group in the year 2012. Significant increases in net sales combined with a good performance in the collection of trade receivables and sound investment decisions allowed the Octapharma Group to end the year 2012 with increased profitability, significantly without bank loans.
-----------------------------------------------------------
It is with pleasure that we can announce the availability of two more peer-reviewed papers on our Human-cl rhFVIII as the first native and truly human cell-derived rFVIII. Beside the already available paper on the human cell line and manufacturing characteristics,
-----------------------------------------------------------------
The first peer-reviewed publication on Octapharma`s Human-cl rhFVIII has been published in the European Journal of Haematology.
The article can be read by clicking the following link:
The present paper addresses:
-
The rationale for developing a human instead of a hamster cell line for rFVIII production in order to reduce rFVIII immunogenicity
-
The rationale why the usage of the HEK 293F cell line may lead to less FIII inhibitors and allergic reactions than hamster cell-lines
-
How Octapharma managed to be the first company worldwide to adapt the HEK293F cell line for the commercial production of a high quality rFVIII
-
The extensive pathogen safety measures undertaken to guarantee the highest level of virus and prion safety
-
The capacity of the newly developed production and purification process in order to eliminate any potential contaminations of the final product
-
How it was possible to use the human cell line as a production cell line without adding any animal-or human-derived materials
-
How we developed the most modern manufacturing process for a truly human rFVIII to ensure the highest level of inhibitor safety, purity and pathogen safety
------------------------------------------------------------------
Den Baubeginn in Heidelberg zeigt das Videoportal des Rhein-Neckar Fernsehen. Die Rhein-Neckar-Zeitung berichtete über die Grundsteinlegung: "Ein Traumschiff soll die Forschung beflügeln" (Artikel vom 09.07.2010).
Die Eröffnung des neuen Standorts in unmittelbarer Nachbarschaft zum Deutschen Krebsforschungszentrum (DKFZ) ist für Anfang 2012 geplant.
Schwerpunkt wird die Grundlagenforschung sein, konzentriert auf die Kernkompetenzen des Unternehmens: Immunologie, Hämatologie/Blutgerinnung sowie Intensiv- und Notfallmedizin. Bauherrin des neuen Zentrums ist die Octapharma Biopharmaceuticals GmbH, ein biotechnologisches Forschungsunternehmen mit Fokus auf die Herstellung von Proteinen mittels humanen Zelllinien.
Geschäftsführerin Carola Schröder wird mit Ihren Mitarbeitern aus Martinsried bei München nach Heidelberg umziehen und zusätzlich hochqualifizierte Mitarbeiter aus der Metropolregion rekrutieren. Mit der Eröffnung des neuen Standorts soll auch das Personal aufgestockt werden. Geplant ist, dass zunächst 60, später bis zu 100 Octapharma-Mitarbeiter in Heidelberg forschen.